Avastin (bevacizumab) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

684 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avastin (bevacizumab) / Roche
2021-004278-76: Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance in patients with advanced ovarian cancer after complete initial surgery

Not yet recruiting
2
390
Europe
NIRAPARIB, Bevacizumab, [Niraparib], [bevacizumab], Capsule, hard, Concentrate for solution for infusion, ZEJULA, MVASI
ARCAGY-GINECO, GSK
Advanced ovarian, tubal or peritoneal cancer, Ovarian cancer, Diseases [C] - Cancer [C04]
 
 
ACTRN12611000300976: Bevacizumab intravitreal injection in the treatment of patients with Central Retinal Vein Occlusion.

Recruiting
2
22
 
Royal Adelaide Hospital, Royal Adelaide Hospital
Central retinal vein occlusion (CRVO)
 
 
ACTRN12609000904279: Study of changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer

Recruiting
2
40
 
Georgios Kesisis, Hellenic Association for Cancer Research
metastatic breast cancer
 
 
jRCT1041200068: Phase II study of atezolizumab + bevacizumab combination therapy in patients with advanced hepatocellular carcinoma with a history of drug therapy

Active, not recruiting
2
28
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche
Kanazawa University Hospital
Hepatocellular carcinoma
 
 
JACCRO CC-13AR, UMIN000018412: Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tu

No longer recruiting
2
300
Japan
Avastin (bevacizumab) - Roche, irinotecan - Generic mfg., oxaliplatin - Generic mfg., 5-fluorouracil - Generic mfg., Erbitux (cetuximab) - Eli Lilly, EMD Serono
Colorectal cancer
 
 
jRCT2080221353: A Phase II, open-label, randomized trial of RG1415 plus bevacizumab versus RG1415 alone as a 1st line therapy for advanced or metastatic NSCLC patients with EGFR mutation.

Unknown status
2
150
Japan
erlotinib - Generic mfg., Avastin (bevacizumab) - Roche
Chugai Pharmaceutical Co., Ltd.
Non-small cell lung cancer with EGER mutation (1st line therapy)
 
 
ACTRN12611000888965: Avastin versus Triamcinolone for Diabetic Macular Edema at the time of Cataract Surgery

Recruiting
2
100
 
Royal Victorian Eye and Ear Hospital
Diabetic Macular Oedema, Cataracts
 
 
PIT-1, jRCTs031180402:

Completed
2
85
Japan
Avastin (bevacizumab) - Roche
Juntendo University Hospital
Primary lung cancer
 
 
ACTRN12618001480279: Comparing alternating oxaliplatin and irinotecan chemotherapy versus standard of care for metastatic colorectal cancer.

Recruiting
2
140
 
The Walter and Eliza Hall Institute of Medical Research, Victorian Comprehensive Cancer Centre
Metastatic Colorectal Cancer
 
 
NEJ043, jRCTs031190066: A Phase 2 Study of atezolizumab + carboplatin + paclitaxel + bevacizumab for previously-treated patients with NSCLC harboring EGFR mutations.

Completed
2
60
Japan
Tecentriq (atezolizumab) - Roche, carboplatin - Generic mfg., paclitaxel - Generic mfg., Avastin (bevacizumab) - Roche
Niigata University Medical and Dental Hospital
Non-squamous non-small cell lung cancer
 
 
ChiCTR1800020333: Nab-paclitaxel, Nedaplatin plus Bevacizumab as a first-line therapy in advanced lung adenocarcinoma patients with driven gene negative

Not yet recruiting
2
81
 
Nab-paclitaxel, Nedaplatin plus Bevacizumab
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd.
Gastric cancer
 
 
NCT00707096: Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Active, not recruiting
2
46
US
bevacizumab, cisplatin, fluorouracil, three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, Adjuvant therapy
University of Medicine and Dentistry New Jersey, National Cancer Institute (NCI), Radiation Therapy Oncology Group
Head and Neck Cancer
03/08
 
2008-003006-34: A multicenter, randomized, phase II clinical trial to evaluate the effect of Avastin in combination with neoadjuvant treatment regimens on the molecular and metabolic characteristics and changes in the primary tumors with reference to the obtained responses in patients with large primary HER2 negative breast cancers.

Not yet recruiting
2
200
Europe
Concentrate for solution for infusion, Avastin
Kreftklinikken Radiumhospitalet, Roche Norge AS, Kreftsenteret Ullevål Universitetssykehus
HER2 negative breast cancer
 
 
2008-007928-25: ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAPIE DANS LE CANCER COLO-RECTAL METASTATIQUE

Ongoing
2
188
Europe
bevacizumab, irinotécan, acide folinique, 5-Fluorouracile, Intravenous infusion, Avastin
Fédération Francophone de Cancérologie Digestive - FFCD
ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAPIE DANS LE CANCER COLO-RECTAL METASTATIQUE
 
 
2009-016926-15: Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment for Coroidal Neovascularization (CNV) secondary to exudative Age Related Macular Degeneration (AMD)

Ongoing
2
24
Europe
Concentrate for solution for infusion, AVASTIN
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
exudative Age Related Macular Degeneration
 
 
NCT00403468: Combination Chemotherapy and Bevacizumab in Treating Patients With Recurrent, Unresectable, or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, or Esophageal Cancer

Recruiting
2
49
US
bevacizumab, cisplatin, docetaxel, fluorouracil, leucovorin calcium
Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
10/10
 
NCT01107652: Pazopanib Hydrochloride With or Without Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Squamous Non-Small Cell Lung Cancer Previously Treated With Bevacizumab

Recruiting
2
72
US
pazopanib hydrochloride, pemetrexed disodium
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Lung Cancer
03/11
 
2010-022065-10: Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within the Swedish Association of Breast Oncologists SABO-2010-01

Ongoing
2
40
Europe
Concentrate for solution for infusion, Film-coated tablet, Avastin, Xeloda, Sendoxan
Sahlgrenska University Hospital
Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC) can also be included. Patients with TNBC will not receive endocrine therapy., Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC), Diseases [C] - Cancer [C04]
 
 
2012-000165-20: Clinical trial to evaluate the results of intravitreal bevacizumab injections in cases of recurrence of macular edema secondary to retinal vein thrombosis previously treated with ozurdex Ensayo Clínico para evaluar los resultados del tratamiento con inyecciones intravítreas de bevacizumab en los casos de recidiva del edema macular secundario a trombosis de vena de retina que ha sido tratado previamente con ozurdex

Ongoing
2
53
Europe
Solution for infusion, AVASTIN
Fundación para la Investigación biomédica del Hospital Universitario Ramón y Cajal. Madrid, Concedida ayuda a la investigación clínica independiente 2011.MSPI. EC11-136
Macular edema secondary to retinal vein occlusion Edema macular secundario a oclusiones venosas de retina, Visual loss due to Macular edema after retinal vein occlusion La pérdida de visión por edema macular debido a trombosis venosa de la retina, Diseases [C] - Eye Diseases [C11]
 
 
NCT01330212: PET-Guided Chemotherapy and Hormone Therapy in Treating Women With Previously Untreated Invasive Breast Cancer

Recruiting
2
60
US
bevacizumab, trastuzumab, capecitabine, cyclophosphamide, docetaxel, epirubicin hydrochloride, vinorelbine tartrate, gene expression analysis, microarray analysis, neoadjuvant therapy, positron emission tomography, therapeutic conventional surgery
Auxilio Mutuo Cancer Center
Breast Cancer
03/13
 
ACTRN12611000033943: A phase II study of oxaliplatin/5-FU/Avastin and concurrent radiation in patients with simultaneous primary and metastatic rectal cancer

Active, not recruiting
2
30
 
Peter MacCallum Cancer Centre, Roche Products Pty Limited
Primary rectal cancer, Metastatic rectal cancer
 
 
ChiCTR-ONRC-12002397: Neoadjuvant chemotherapy of bevacizumab, gemcitabine and cisplatin in stage IIIA non-small cell lung cancer: control and multi-center study

Recruiting
2
140
 
Chemotherapy combined with AVASTIN ;Chemotherapy
The first affiliated hospital of Guangzhou MC; Nanfang Hospital, Nil
Non-small cell lung cancer
 
 
2013-005549-35: To establish the safety and tolerability of intravitreous administration of altering regimens of Fovista? (Anti-PDGF-B pegylated aptamer) administered in combination with Anti-VEGF therapy (Lucentis®, Avastin® or Eylea®) in subjects with subfoveal neovascular age-related macular degeneration. Evaluar la seguridad y la tolerabilidad de la administración intravítrea de diferentes pautas de Fovista? (aptámero pegilado anti-PDGF-B) y el tratamiento anti-VEGF (Lucentis®, Avastin® o Eylea®) en pacientes con degeneración macular neovascular asociada a la edad.

Ongoing
2
25
Europe
Fovista, Lucentis, Eylea, Avastin, E10030, Solution for injection, Lucentis 10 mg/mL, Eylea, Avastin
Barcelona Macula Foundation Research for Vision, Barcelona Macula Foundation
Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Diseases [C] - Eye Diseases [C11]
 
 
2014-000394-39: Full dose S1 compared to reduced dose S-1/oxaliplatin. First-line treatment for older patients with metastic colorectal cancer. S1 eller S1/oxaliplatin som 1. linje behandling til ældre patienter med metastaserende kolerektalcancer.

Ongoing
2
160
Europe
oxaliplatin, irinotecan, Avastin, S1, 23388, Concentrate and solvent for solution for injection/infusion, Concentrate and solvent for solution for infusion, Capsule, hard, Oxaliplatin, Irinotecan, Avastin, Teysuno
Odense University Hospital, Odense University Hospital
Treatment of older (≥ 70 years) patients with metastatic colorectal cancer, Colorectal cancer, Diseases [C] - Cancer [C04]
 
 
NCT00334815: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Checkmark P1/2 data - ASCO/ASTRO/IASLC 2012
Sep 2012 - Sep 2012: P1/2 data - ASCO/ASTRO/IASLC 2012
Checkmark P1/2 data-ASCO
Jun 2012 - Jun 2012: P1/2 data-ASCO
Checkmark P2 data 1st line NSCLC
More
Active, not recruiting
2
29
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Tripegfilgrastim, Udenyca, Ziextenzo, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
07/14
02/25
NCT00861705: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Neo-adjuvant bevacizumab-containing therapy in TNBC
Dec 2013 - Dec 2013: Neo-adjuvant bevacizumab-containing therapy in TNBC
Active, not recruiting
2
454
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
08/14
02/25
BAGEL, UMIN000013586: Randomised phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with EGFR mutant non-squamous non small cell lung cance

Recruiting
2
90
Japan
gefitinib - Generic mfg., Avastin (bevacizumab) - Roche
National Hospital Organization Nagoya Medical Center, NPO-OSCR
Non small cell lung cancer
 
 
2013-001179-19: Prospective phase II study of Gemcitabine plus platinium salt in combination with bevacizumab (Avastin®) for metastatic collecting duct carcinoma.

Not yet recruiting
2
41
Europe
Solution for infusion, Powder for solution for infusion, Avastin, CISPLATINE, CARBOPLATINE, GEMZAR
UNICANCER, ROCHE Laboratories
Metastatic collecting duct carcinoma, Metastatic collecting duct carcinoma, Diseases [C] - Ear, nose and throat diseases [C09]
 
 
2014-000543-33: A trial comparing 2 chemotherapies with personalized treatment with new drugs in patients with colorectal cancer Een studie die twee gepersonaliseerde behandelingen met nieuwe medicijnen vergelijkt bij patiënten met colorectale kanker

Ongoing
2
175
Europe
Concentrate for solution for infusion, VECTIBIX, AVASTIN, ADRUCIL, ELOXATIN
Antwerp University Hospital, Amgen
metastatic unresectable colorectal cancer (mCRC) ., METASTATIC COLON CANCER, Diseases [C] - Cancer [C04]
 
 
NCT01665443: Bevacizumab and Docetaxel in Treating Older Patients With Stage III-IV Non-Small Cell Lung Cancer

Active, not recruiting
2
8
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, docetaxel, RP 56976, Taxotere, TXT
Barbara Ann Karmanos Cancer Institute, Genentech
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
12/14
 
NCT00977574: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
2
349
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Cancer, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
01/15
03/25
B-DOCT, NCT01359397 / 2010-022699-30: Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

Active, not recruiting
2
Europe
Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
The Netherlands Cancer Institute
Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
05/15
 
NCT01879306: Abraxane Plus Bevacizumab Versus Ipilimumab as 1st Line Therapy for BRAFwt Metastatic Melanoma

Recruiting
2
176
US
paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, ipilimumab, anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody, MDX-010, MDX-CTLA-4, monoclonal antibody CTLA-4, laboratory biomarker analysis, pharmacological study, pharmacological studies
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Stage IV Melanoma
06/15
 
NCT01946529: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Active, not recruiting
2
24
US
vincristine, Oncovin(R), doxorubicin, Adriamycin(R), cyclophosphamide, Cytoxan(R), ifosfamide, Ifex(R), etoposide, VP-16, Vepesid(R), temozolomide, Temodar(R), temsirolimus, CCI-779, Torisel^TM, bevacizumab, rhumab VEGF, Avastin(R), sorafenib, BAY-43-9006, Nexavar(R), surgery, therapeutic conventional surgery, radiation, proton beam radiation therapy, external beam radiation therapy, brachytherapy
St. Jude Children's Research Hospital, University of Tennessee, University of Florida, Nemours Children's Clinic
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
08/15
07/26
2015-000535-33: Is it possible to make breast cancer visible during surgery by using a fluorescent tumor-specific dye during breast cancer surgery? Kan borstkanker zichtbaar gemaakt worden met een fluorescerende stof zodat de chirurg tijdens de operatie de tumor beter kan onderscheiden van gezond weefsel.

Ongoing
2
27
Europe
Bevacizumab-800Cw, Solution for injection/infusion
University Medical Center Groningen, Dutch Cancer Foundation
Patients with breast cancer eligible for surgery, Breast cancer Borstkanker, Diseases [C] - Cancer [C04]
 
 
2007-000585-21: Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma.

Ongoing
2
20
Europe
Avastin (bevacizumab), Avastin, Avastin
Royal Victoria Eye and Ear hospital
Rubeotic glaucoma secondary to ischaemic proliferative retinopathies
 
 
2004-004546-41: A phase II trial assessing bevacizumab in the treatment of advanced or metastatic angiosarcoma

Ongoing
2
10
Europe
Bevacizumab, RO 4876646, Avastin, Avastin
Helsinki University Central Hospital
patients with advanced or metastatic angiosarcoma
 
 
2005-003209-10: VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment

Ongoing
2
20
Europe
Bevacizumab, paclitaxel, carboplatin, RO 4876646, Avastin, Avastin
Tampere University Hospital
FIGO Stage III-IV serous epithelial ovarian carcinoma
 
 
2005-006182-14: Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies

Ongoing
2
30
Europe
AVASTIN INFUS 1FL 100MG, AVASTIN INFUS 1FL 100MG
UNIVERSITA DEGLI STUDI DI UDINE
Exudative maculopathy associated with retinovascular disease
 
 
2006-001779-39: Phase II trial FOLFOX combined with Bevacizumab, Cetuximab and Imatinib in patients with advanced untreated colorectal cancer

Ongoing
2
50
Europe
Fluorouracil, GLIVEC*120CPS 100MG, ERBITUX*INFUS 1FL 50ML 2MG/ML, AVASTIN, ELOXATIN, LEDERFOLIN, GLIVEC*120CPS 100MG, ERBITUX*INFUS 1FL 50ML 2MG/ML, AVASTIN, ELOXATIN, LEDERFOLIN
Azienda Ospedaliera Universitaria S.Martino - U.O. Oncologia Medica - Genova
advanced untreated colorectal cancer in disease stage IV for which, second recent line-guide Poston JCO, October 2005 not is indication to the surgical treatment and that they have not been she deals to you in previous with x-ray.
 
 
2006-002887-25: Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell\'Italia Meridionale. (GOIM).

Ongoing
2
64
Europe
AVASTIN*INFUS 1FL 100MG, LEDERFOLIN*EV 1FL LIOF 175MG, FLUOROURACILE TEVA*IV FL 5G, CAMPTO*1FL 100MG/5ML, AVASTIN*INFUS 1FL 100MG, LEDERFOLIN*EV 1FL LIOF 175MG, FLUOROURACILE TEVA*IV FL 5G, CAMPTO*1FL 100MG/5ML
GOIM GRUPPO ONCOLOGICO MERIDIONALE
untreated patients with advanced colorectal cancer.
 
 
2006-002992-42: A phase II study to evaluate the efficacy of bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer.

Ongoing
2
65
Europe
AVASTIN*INFUS 1FL 100MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG, XELODA*120CPR RIV 500MG
AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"
Locally advanced pancreatic cancer.
 
 
2006-001007-11: OPEN-LABEL, MULTICENTER, PHASE II STUDY OF FIRST- LINE BI-WEEKLY IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV (FOLFOXIRI) IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER.

Ongoing
2
39
Europe
AVASTIN*INFUS 1FL 400MG, CAMPTO*1FL 100MG/5ML, ELOXATIN*IV 1FL POLV 100MG, ELOXATIN*IV 1FL POLV 50MG, LEVOFOLENE*EV 1FL 175MG, FLUOROURACILE TEVA*IV FL 5G, FLUOROURACILE TEVA*IV 5FL250MG, AVASTIN*INFUS 1FL 400MG, CAMPTO*1FL 100MG/5ML, ELOXATIN*IV 1FL POLV 100MG, ELOXATIN*IV 1FL POLV 50MG, LEVOFOLENE*EV 1FL 175MG, FLUOROURACILE TEVA*IV FL 5G, FLUOROURACILE TEVA*IV 5FL250MG
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
IN PATIENTS WITH METASTATIC COLORECTAL CANCER.
 
 
2006-003929-83: Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.

Ongoing
2
80
Europe
XELODA*60CPR RIV 150MG, TAXOTERE*INFUS FL 20MG/0,5ML+F, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG, TAXOTERE*INFUS FL 20MG/0,5ML+F, AVASTIN*INFUS 1FL 100MG
GRUPPO ONCOLOGICO ITALIANO DI RICERCA
Patients with advanced breast cancer
 
 
2006-001777-19: A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.

Ongoing
2
140
Europe
daunorubicin, cytarabin, Avastin, Avastin
HOVON foundation
Acute myeloid leukaemia (AML), AML FAB M0-M2 or M4-M7;diagnosis with refractory anemia with excess of blasts (RAEB) or refractory anemia with excess of blasts in transformation (RAEB-T) with an IPSS score ≥ 1.5
 
 
2007-000658-30: Randomised controlled trial of Intravitreal Bevacizumab vs. conventional treatment for proliferative diabetic retinopathy.

Ongoing
2
20
Europe
Avastin (bevacizumab), Avastin (bevacizumab), Avastin (bevacizumab)
Royal Victoria Eye and Ear hospital
Proliferative diabetic retinopathy
 
 
2006-005110-12: Evaluation de l\'association Fofiri 3 et bévacizumab (Avastin) dans le traitement des cadénocarcinomes colorectaux métastasiques

Ongoing
2
47
Europe
Irinotecan, bevacizumab, 5 Fluorouracile, IRINOTECAN, Avastin, fluorouracile, IRINOTECAN, Avastin, fluorouracile
CHU de Besançon
colorectal adenocarcinoma with metastases
 
 
2007-003484-45: PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER

Ongoing
2
23
Europe
AVASTIN, ELOXATIN, FLUOROURACILE TEVA, CAMPTO, LEDERFOLIN, AVASTIN, ELOXATIN, FLUOROURACILE TEVA, CAMPTO, LEDERFOLIN
ISTITUTO ONCOLOGICO VENETO
UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
 
 
2006-006058-83: Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study)

Ongoing
2
312
Europe
Avastin, Xeloda, paclitaxel, paclitaxel, Avastin, Xeloda, Taxol, Avastin, Xeloda, Taxol
VU Medisch Centrum
locally recurrent or metastatic breast cancer
 
 
2006-002152-16: Phase II randomized study of intravenous bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in patients with locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall.

Ongoing
2
46
Europe
AVASTIN*INFUS 1FL 400MG, NAVELBINE*1CPS 30MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 20MG, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG, AVASTIN*INFUS 1FL 400MG, NAVELBINE*1CPS 30MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 20MG, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG
ISTITUTO EUROPEO DI ONCOLOGIA
locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall.
 
 
2006-003170-99: Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration

Ongoing
2
54
Europe
Anecortave Acetate, AVASTIN*INFUS 1FL 100MG, AVASTIN*INFUS 1FL 100MG
UNIVERSITA DEGLI STUDI DI UDINE
Exudative age-related macular degeneration
 
 
2007-004053-28: Combined chemio-radioterapy regimen of 5-FU plus irinotecan followed by chemotherapy for the treatment of colorectal cancer with resectable metastases at diagnosis

Ongoing
2
18
Europe
FLUOROURACILE ICN, LEDERFOLIN, IRINOTECAN MAYNE, AVASTIN, ERBITUX, FLUOROURACILE ICN, LEDERFOLIN, IRINOTECAN MAYNE, AVASTIN, ERBITUX
ISTITUTO ONCOLOGICO VENETO
RECTAL CARCINOMA WITH RESECTABLE METASTASES AT DIAGNOSIS
 
 
2007-001418-17: efficacy of treatment with bevacizumab,in the macular degeneration.

Ongoing
2
40
Europe
AVASTIN, AVASTIN
AZIENDA OSPEDALIERA DI PADOVA
macular degeneretion aging dependent.
 
 
2007-005644-24: Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients

Ongoing
2
20
Europe
Avastin, Avastin
AMC-UvA
Primary Glioblastoma Multiforme
 
 
2007-007787-25: Use of subconjunctival Bevacizumab (Avastin) in treatment of corneal neovascularization non curable with standard protocols (topical and sistemic steroids).

Ongoing
2
30
Europe
AVASTIN, AVASTIN
AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
Corneal neovascularization
 
 
2007-002682-12: Protocol GI-04A PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (XELODA) IN FRAIL PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER

Ongoing
2
50
Europe
Bevacizumab, Xeloda, RO4876646, Avastin, Capecitabine, Avastin, Capecitabine
ICORG
FRAIL PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER
 
 
2007-001553-26: A randomized, double-masked study with intraocular bevacizumab (Avastin®) compared with intraocular triamcinolone (Volon A®) in patients with clinical significant diabetic macular edema

Ongoing
2
30
Europe
Bevacizumab, triamcinolone, L01XX28, H02AB08, Avastin, Volon A, Avastin, Volon A
Vienna Medical University, Dept. of Ophthalmology
Patients with persisting macular edema due to diabetic retinopathy.
 
 
2007-005523-15: A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy.

Ongoing
2
56
Europe
bevacizumab, erlotinib, Avastin, tarceva, Avastin, tarceva
Radboud University Medical Centre
advanced non-small cell lung cancer
 
 
2006-005197-51: Accelerated growth of synchronous colorectal liver metastases: effects of neo-adjuvant therapy

Ongoing
2
60
Europe
bevacizumab, Avastin, Avastin
The Netherlands Cancer Institute/ Antoni van Leeuwenhoek hospital, Radboud University Nijmegen Medical Center
synchronous liver metastases in patients with the primary colorectal tumour in situ
 
 
2008-002775-28: Evaluation de l\'association irinotécan/bévacizumab utilisée en néo-adjuvant et en adjuvant d\'une radiochimiothérapie avec témozolomide concomitant pour les glioblastomes non résécables. Etude de phase II randomisée avec comparaison à une radiochimiothérapie avec témozolomide concomitant et adjuvant

Ongoing
2
126
Europe
témozolomide, IRONOTECAN, BEVACIZUMAB, TEMODAL® 5mg, TEMODAL® 20mg, TEMODAL® 100mg, TEMODAL® 250mg, CAMPTO ®, AVASTIN ®, TEMODAL® 5mg, TEMODAL® 20mg, TEMODAL® 100mg, TEMODAL® 250mg, CAMPTO ®, AVASTIN ®
Centre Georges François Leclerc
GLIOBLASTOMES MULTIFORME (GBM) NON RESECABLES
 
 
2007-006025-27: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast cancer Studio di fase II di chemioterapia metronomica orale con ciclofosfamide e capecitabina combinata con bevacizumab e erlotinib (BEXE), piu\' trastuzumab nei tumori positivi per HER2/neu (BEXET)nel cancro della mammella avanzato

Ongoing
2
66
Europe
ENDOXAN BAXTER*50CPR RIV 50MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG 4ML, TARCEVA*30CPR RIV 150MG, HERCEPTIN*EV 1FL 150MG, ENDOXAN BAXTER*50CPR RIV 50MG, XELODA*120CPR RIV 500MG, AVASTIN*INFUS 1FL 100MG 4ML, TARCEVA*30CPR RIV 150MG, HERCEPTIN*EV 1FL 150MG
ISTITUTO EUROPEO DI ONCOLOGIA
advanced or metastatic breast cancer cancro della mammella localmente avanzato o metastatico
 
 
2010-020545-26: BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS

Ongoing
2
18
Europe
AVASTIN, AVASTIN
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
 
 
2008-006191-30: Biweekly Bevacizumab and weekly Carboplatin and Paclitaxel as II line therapy in advanced Malignant Melanoma patients: a phase II study

Ongoing
2
54
Europe
Concentrate for solution for infusion
ISTITUTO DERMOPATICO IMMACOLATA
patients with histologically confirmed progressive metastastic melanoma progressed after first line chemotherapy.
 
 
2008-006755-44: METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II

Ongoing
2
25
Europe
AVASTIN, AVASTIN, AVASTIN
HOSPICES CIVILS DE LYON
Maladie de Rendu-Osler
 
 
2008-006145-13: Estudio fase II, abierto, no aleatorizado, de bevacizumab, cisplatino y pemetrexed como primera línea de tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) y no epidermoide, en estadio IIIB – con derrame pleural/pericárdico maligno - o IV.

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Ongoing
2
28
Europe
cisplatino, AVASTIN 25 mg/ml concentrado para solución para perfusión, ALIMTA 500 mg polvo para concentrado para solución para perfusión, ALIMTA 100 mg polvo para concentrado para sol. para perfusión, AVASTIN 25 mg/ml concentrado para solución para perfusión, ALIMTA 500 mg polvo para concentrado para solución para perfusión, ALIMTA 100 mg polvo para concentrado para sol. para perfusión
ASONMEC (Asociación de Oncología Medica del Hospital de Cruces)
CÁNCER DE PULMÓN NO MICROCÍTICO Y NO EPIDERMOIDE, EN ESTADIO IIIB – CON DERRAME PLEURAL/PERICÁRDICO MALIGNO - O IV
 
 
2008-006265-93: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).

Ongoing
2
60
Europe
Avastin®, Avastin ®, Avastin ®
St Eriks Eye Hospital
Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
 
 
2008-008259-41: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial.

Ongoing
2
40
Europe
RPE-choroid graft, NA, NA, Avastin, NA, Avastin
Rotterdam Eye Hospital
Age related macular degeneration and either of the following conditions:1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.
 
 
2008-006128-79: Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients

Ongoing
2
40
Europe
Campto, ELOXATIN, Avastin, Taxotere, Campto, ELOXATIN, Avastin, Taxotere
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH, Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Unresectable locally advanced or metastatic Gastric Cancer
 
 
2009-011377-33: AN ASSESSMENT OF IMAGING AND CIRCULATING BIOMARKERS IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED WITH THE ANTI-VEGF MONOCLONAL ANTIBODY BEVACIZUMAB

Ongoing
2
70
Europe
Bevacizumab, Avastin
The Christie NHS Foundation Trust
Metastatic colorectal cancer
 
 
2009-011479-62: Visualizing VEGF producing lesions in Von Hippel-Lindau disease

Ongoing
2
30
Europe
89Zr-SucDf-bevacizumab,
University Medical Center Groningen
To determine if disease associated lesions in patients with VHLD can be visualized with 89Zr-bevacizumab PET scans.
 
 
2009-012010-52: Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma

Ongoing
2
118
Europe
Avastin, Avastin
Department of Oncology, Aarhus University Hospital
Patient with previously untreated Metastatic Renal Cell Carcinoma
 
 
2009-012186-63: Landelijke Werkgroep voor Neuro-Oncologie trial (LWNO 0901)Randomized phase II study of Bevacizumab versus Bevacizumab plus Lomustine in patients with recurrent Glioblastoma: the BELOB trial

Ongoing
2
86
Europe
Avastin, Belustine, Avastin, Belustine
Erasmus MC, more specifically for and on behalf of the department of Neurology/Neuro-Oncology
Patients with recurrent glioblastoma multiforme who failed combined chemo-irradiation with temozolomide.
 
 
2009-016453-17: Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide � trastuzumab and endocrine therapy for inflammatory breast cancer

Ongoing
2
59
Europe
ENDOXAN BAXTER*50CPR RIV 50MG, PACLITAXEL EB*INF FL100MG 6MG/, PACLITAXEL EB*INF FL300MG 6MG/, CARBOPLATINO EBE.*EV450MG/45ML, HERCEPTIN*EV 1FL 150MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML, ENDOXAN BAXTER*50CPR RIV 50MG, PACLITAXEL EB*INF FL100MG 6MG/, PACLITAXEL EB*INF FL300MG 6MG/, CARBOPLATINO EBE.*EV450MG/45ML, HERCEPTIN*EV 1FL 150MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML
ISTITUTO EUROPEO DI ONCOLOGIA
Inflammatory breast cancer
 
 
2009-017776-24: A pilot study evaluating response to induction chemotherapy with oxaliplatin, capecitabine and bevacizumab in patients with extensive peritoneal carcinomatosis of colorectal origin.

Ongoing
2
35
Europe
Xeloda, Avastin, Xeloda, Avastin
Induction chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer
 
 
2010-021968-15: NOT RANDOMISED OPEN LABEL STUDY TO COMPARE EFFICACY OF BEVACIZUMAB (AVASTIN, ROCHE) VERSUS RANIBIZUMAB (LUCENTIS, NOVARTIS) ADMINISTERED BY INTRAVITREAL INJECTION IN PATIENTS WITH EXUDATIVE AGE RELATED MACULAR DEGENERATION WITH VISUAL ACUITY >= 2/10

Ongoing
2
205
Europe
AVASTIN, LUCENTIS, AVASTIN, LUCENTIS
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
exudative age related macular degeneration
 
 
2009-012942-22: Essai de phase II, randomisé multicentrique, évaluant l\'efficacité d\'une chimiothérapie standard à base de fluoropyrimidine associée au cétuximab ou au bévacizumab, chez des patients kras sauvage, atteints d\'un cancer colorectal métastatique, en progression après une 1ere ligne de traitement avec bévacizumab.

Ongoing
2
132
Europe
ELOXATINE, CAMPTO, ELVORINE, FLUOROURACILE, ERBITUX, AVASTIN, ELOXATINE, CAMPTO, ELVORINE, FLUOROURACILE, ERBITUX, AVASTIN
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
Cancer colorectal métastatique (CCM), KRAS sauvage, nécessitant un traitement de 2éme ligne.
 
 
2010-021248-16: ANGIOGENESIS IMAGING WITH CONTRAST-ENHANCED ULTRASOUND (CEUS) IN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH BEVACIZUMAB

Ongoing
2
45
Europe
Powder for suspension for injection
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Patients affected by advanced colorectal carcinoma
 
 
2010-019463-10: MULTICENTER PHASE II STUDY FOR THE EVALUATION OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER STUDIO MULTICENTRICO DI FASE II PER LA VALUTAZIONE DELL\'ASSOCIAZIONE DI BEVACIZUMAB (AVASTIN), OXALIPLATINO E CAPECITABINA (XELODA) NEL TRATTAMENTO DEI PAZIENTI ANZIANI (ELDERLY) AFFETTI DA CANCRO DEL COLON-RETTO AVANZATO (BOXE TRIAL)

Ongoing
2
44
Europe
XELODA, OXALIPLATINO RAT, AVASTIN, XELODA, OXALIPLATINO RAT, AVASTIN
AZIENDA OSPEDALIERA S. CARLO
advanced colorectal cancer cancro del colon-retto avanzato.
 
 
2010-022183-12: Phase II study of metronomic oral Vinorelbine plus Bevacizumab as first line treatment for metastatic breast cancer patients

Ongoing
2
46
Europe
NAVELBINE*1CPS 20MG, NAVELBINE*1CPS 30MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML, NAVELBINE*1CPS 20MG, NAVELBINE*1CPS 30MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML
ISTITUTO EUROPEO DI ONCOLOGIA
Metastatic breast cancer
 
 
2010-022077-33: Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer

Ongoing
2
43
Europe
AVASTIN, CARBOPLATINO MAYNE*EV 50MG/5ML, ANZATAX, AVASTIN, CARBOPLATINO MAYNE*EV 50MG/5ML, ANZATAX
AZIENDA OSPEDALIERA POLICLINICO DI MODENA
Patient with early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer
 
 
2009-016080-11: A COMPREHENSIVE AND TARGETED THERAPY APPROACH IN PEDIATRIC MALIGNANT PONTINE GLIOMAS

Ongoing
2
16
Europe
gemzar, ledertepa, toposin, Alkeran, avastin, tarceva, certican, campto, carbosin, gemzar, ledertepa, toposin, Alkeran, avastin, tarceva, certican, campto, carbosin
VU University Medical Center
Pediatric malignant pontine gliomas
 
 
2010-022091-31: Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study.

Ongoing
2
132
Europe
AVASTIN*INFUS 1FL 400MG 16ML, FLUOROURACILE TEVA*IV 5G 100ML, ELOXATIN*INFUS 1FL 40ML 5MG/ML, XELODA*120CPR RIV 500MG, LEDERFOLIN*INFUS 1FL 100MG, AVASTIN*INFUS 1FL 400MG 16ML, FLUOROURACILE TEVA*IV 5G 100ML, ELOXATIN*INFUS 1FL 40ML 5MG/ML, XELODA*120CPR RIV 500MG, LEDERFOLIN*INFUS 1FL 100MG
GOIM GRUPPO ONCOLOGICO MERIDIONALE
Oncologic patients
 
 
2011-005495-42: Individualised choise of 1.line chemotherapy of metastatic colo-rectal cancer. Can the blood test: TIMP-1 help the doctor to choose the best chemotherapy for the individual patient? Individualiseret valg af første linie kemoterapi af tarmkræft med spredning.Støtter blodprøven: TIMP-1 (cancer markør) lægen at foretage bedste valg af 1.linie kemoterapi?

Ongoing
2
210
Europe
Xeloda, Avastin, oxaliplatin, irinotecan, WC500058151, WC500029271, Xeloda, Avastin, oxaliplatin, irinotecan, Xeloda, Avastin, oxaliplatin, irinotecan
Kell Osterlind, Rigshospitalet
Metastatic colon or rectal cancer Metastatisk tarmkræft der udgår fra tyk- eller endetarm
 
 
2012-002321-30: Medical treatment for patients with cancer of the esophagus or stomach Medicinsk behandling til patienter med kræft i spiserøret eller mavesækken

Ongoing
2
90
Europe
Irinotecan, 25363, Irinotecan, Avastin, Irinotecan, Avastin
Odense University Hospital, Det nationale koordinationsudvalg vedr. eksperimentel kræftbehandling (NKU)
Patients with esophagus or gastric cancer and who are platinum resistant and non-resectabel
 
 
2012-001020-35: A clinical phase II trial to compare the efficacy of Bevacizumab monotherapy with standard chemotherapy (dacarbazine) in metastatic melanoma. En fase 2 studie for å sammenligne effekten av Bevacizumab monoterapi med standard kjemoterapi (dacarbazine) ved malignt melanom med metastaser.

Ongoing
2
120
Europe
Bevacizumab, Dacarbazine, Inderal, Renitec, 091652, Avastin (Bevacizumab), Dacarbazine, Inderal (Propranolol), Renitec (Enalapril), Avastin (Bevacizumab), Dacarbazine, Inderal (Propranolol), Renitec (Enalapril)
Helse Bergen HF, Haukeland University Hospital, The Norwegian Cancer Association
Previously treated or untreated histologically confirmed metastatic and unresectable melanoma with radiological (RECIST), clinical or biochemical progressive disease.
 
 
2005-003288-21: INTRAOCULAR BEVACIZUMAB (AVASTIN™) FOR CENTRAL AND BRANCH RETINAL VEIN OCCLUSION STUDY

Ongoing
2
30
Europe
Avastin, EU/1/04/300/001-002, AVASTIN, AVASTIN
Dept. of Ophthalmology, Medical University of Vienna
CENTRAL AND BRANCH RETINAL VEIN OCCLUSION
 
 
2008-001600-23: Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selective anti-VEGF (Macugen) or Pan anti-VEGF (Avastin).

Ongoing
2
20
Europe
AVASTIN, MACUGEN*INIET 1 SIR 0,3MG, AVASTIN, MACUGEN*INIET 1 SIR 0,3MG
AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
Choroidal neovascularization in patients with age-related macular degeneration.
 
 
2011-001512-65: No Ne

Ongoing
2
20
Europe
thalidomide, Celecoxib, Fenofibrate, Etoposide, Cyclophosphamide, Avastin, DepoCyte, Avastin, DepoCyte
Masaryk University, Masaryk University
recurrent or progressive medulloblastoma recidivující/progredující meduloblastom
 
 
2013-002563-25: To study the effect of daily irradiation on the growth of blood vessels in cancer of the gullet Bestuderen van het effect van dagelijkse bestraling op de groei van bloedvaten bij slokdarm kanker

Ongoing
2
50
Europe
Avastin, Avastin
VU University Medical Centre, VU University Medical Centre
Angiogenesis in esophageal cancer Angiogenese in oesofagus carcinoom
 
 
2005-000104-13: A multicenter, placebo-controlled, double-blind randomised phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by six cycles of docetaxel, doxorubucin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer.

Ongoing
2
10
Europe
Bevacizumab, Doxorubicin, Cyclophosphamide, Docetaxel, RO4876646, Avastin, Doxorubicin, Cyclophosphamide, Docetaxel, Avastin, Doxorubicin, Cyclophosphamide, Docetaxel
Translational Oncology Research International
Stage II or Stage III breast cancer
 
 
2005-002808-42: Estudio abierto, no controlado, multicéntrico, de fase II para estudiar la eficacia y seguridad de una combinación de Capecitabina + Bevacizumab, en 1ª línea de tratamiento, en pacientes ancianos no susceptibles de poliquimioterapia con adenocarcinoma colorrectal avanzado o metastático

Ongoing
2
60
Europe
Bevacizumab, capecitabina, Avastin 25 mg/ml concentrado para solución para perfusión, Xeloda 150 mg comprimido con cubierta pelicular, Avastin 25 mg/ml concentrado para solución para perfusión, Xeloda 150 mg comprimido con cubierta pelicular
GRUPO ONCOPAZ
Adenocarcinoma colorrectal localmente avanzado o metastático, no resecable.
 
 
2006-005499-42: Tratamiento de inducción con XELOX-Bevacizumab en el adenocarcinoma localmente avanzado de recto: Estudio fase II

Ongoing
2
44
Europe
AVASTIN 25 mg/ml concentrado para solución para perfusión, AVASTIN 25 mg/ml concentrado para solución para perfusión
ACROSS (Associació Catalana de Recerca Oncològica i les seves implicacions Sanitàries i Socials)
Adenocarcinoma localmente avanzado de recto.
 
 
2007-000488-38: Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomas

Ongoing
2
30
Europe
Bevacizumab, Temozolomide, Oradexon, Bevacizumab, Temozolomide, Oradexon
Academic Medical Center
Patients with a recurrent high grade glioma (after primary treatment)
 
 
2008-000225-19: ENSAYO CLÍNICO DE FASE II, MULTICÉNTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTÁSICO

Ongoing
2
44
Europe
Nexavar®, Avastin®, Nexavar®, Avastin®
GRUPO GETNE
Pacientes con tumor neuroendocrino avanzado y/o metastásico confirmado histológicamente.
 
 
2009-016708-21: Essai multicentrique de phase II évaluant l\'efficcacité et la tolérance de l\'association de bevacizumab, paclitaxel et capecitabine en première ligne chez des patientes atteintes de cancer du sein métastatique ou localement avancé récepteurs triples negatifs .

Ongoing
2
62
Europe
Bevacizumab, Paclitaxel, capecitabine Xeloda, R04876646, Code CIP : 3657456, Code CIP : 3657462, Avastin, paclitaxel, XELODA 150 mg, XELODA 500 mg, Avastin, paclitaxel, XELODA 150 mg, XELODA 500 mg
ARCAGY
Cancer du sein métastatique
 
 
2010-024216-34: Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy

Ongoing
2
334
Europe
Avastin, Aromasin, RO487-6646, Avastin, Aromasin, Avastin, Aromasin
ABCSG (Austrian Breast & Colorectal Cancer Study Group)
Postmenopausal women with histologically proven primary breast cancer of stages I-III scheduled for neoadjuvant endocrine treatment, N+/-, M0, HER2 negative; including patients with lobular breast cancer or patients with any breast cancer histology not suitable for chemotherapy or unlikely to respond to chemotherapy
 
 
2011-002191-16: A Phase II study to assess efficacy and safety of a combination chemotheraphy in first-line treatment with Xeloda + Oxaliplatin + Avastin or Xeloda + Irinotecan + Avastin. At progression of disease (second-line treatment) patient will receive Xeloda + Oxaliplatin + Avastin when received Xeloda + Irinotecan + Avastin in first-line or: At progression of disease (second-line treatment) patient will receive Xeloda + Irinotecan + Avastin if recieved Xeloda + Oxaliplatin + Avastin in first-line.

Ongoing
2
120
Europe
Xeloda, Avastin, Irinotecan, Oxaliplatin, RO0091978, RO04876646, Xeloda, Avastin, IMP with the active substance irinotecan and a marketing authorization in Austria will be used., IMP with the active substance oxaliplatin and a marketing authorization in Austria will be used., Xeloda, Avastin, IMP with the active substance irinotecan and a marketing authorization in Austria will be used., IMP with the active substance oxaliplatin and a marketing authorization in Austria will be used.
Medizinische Universität Wien, Univ.Klink f. Innere Medizin I, Roche Austria GmbH
Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of metastases. Diagnosis of metastatic disease according to RECIST not more than 3 months prior to enrolment No prior chemotherapeutic treatment for metastatic colorectal carcinoma
 
 
2011-006313-33: Intermittent administered erlotinib plus carboplatin, paclitaxel, bebacizumab in patients with advanced lung cancer. Estudio de erlotinib intermitente mas carboplatino, paclitaxel mas bebacizumab en pacientes con cancer de pulmón avanzado.

Ongoing
2
64
Europe
carboplatino, paclitaxel, TARCEVA 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, TARCEVA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, TARCEVA 25 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, AVASTIN 25mg/ml 1 VIAL 100mg/4ml SOL PERF, AVASTIN 25mg/ml 1 VIAL 400mg/16ml SOL PERF, TARCEVA 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, TARCEVA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, TARCEVA 25 mg COMPRIMIDOS RECUBIERTOS CON PELICULA, AVASTIN 25mg/ml 1 VIAL 100mg/4ml SOL PERF, AVASTIN 25mg/ml 1 VIAL 400mg/16ml SOL PERF
Foro Andaluz para el Estudio de Tumores Torácicos (FAETT), ROCHE
Cancer no microcitico / no escamoso de Pulmón avanzado o metastásico
 
 
2011-003301-16: Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer. Studio randomizzato di fase II di confronto tra carboplatino/taxolo vs carboplatino/taxolo/bevacizumab nel tunore dell\'endometrio avanzato o metastatico.

Ongoing
2
108
Europe
AVASTIN*INFUS 1FL 100MG 4ML, PACLITAXEL IPFI*EV 5ML 6MG/ML, CARBOPLATINO TEVA*IV 450MG45ML, AVASTIN*INFUS 1FL 100MG 4ML, PACLITAXEL IPFI*EV 5ML 6MG/ML, CARBOPLATINO TEVA*IV 450MG45ML
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI, Roche
endometrial cancer Carcinoma endometrio
 
 
2012-000987-11: Regional Chemotherapy with Intrahepatic Irinotecan Beads for patients with Livermetastatic Colorectal Cancer. Regionalkemoterapi med irinotecan perler i leveren til patienter med tyk-og endetarms kræft med spredning til leveren

Ongoing
2
50
Europe
Irinotecan, Irinotecan, Irinotecan
Anni Ravnbek Jensen, Terumo Europe
Metastatic colorectal cancer with metastasis confined to the liver Metastatisk colorectal cancer med metastaser isoleret til leveren.
 
 
 

Download Options